We came across a bullish thesis on IDEXX Laboratories, Inc. (IDXX) on Substack by Hidden Market Gems. In this article, we will summarize the bulls’ thesis on IDXX. IDEXX Laboratories, Inc. (IDXX)’s share was trading at $426.69 as of March 11th. IDXX’s trailing and forward P/E were 39.98 and 36.36 respectively according to Yahoo Finance.
A veterinarian examining a pet in a well-equipped animal clinic.
IDEXX Laboratories, founded in 1983 and headquartered in Westbrook, Maine, is a global leader in veterinary diagnostics, water quality testing, and livestock health solutions. Operating at the intersection of animal healthcare, food safety, and environmental monitoring, the company delivers advanced diagnostic systems, software, and services that drive improved health outcomes for animals and communities. With a strong foundation in innovation, IDEXX has built a dominant position in its core markets, particularly in the Companion Animal Group (CAG), which accounts for 89% of total revenue. The company reported $3.66 billion in revenue for 2023, marking a 9% year-over-year increase, driven by strong demand for veterinary diagnostics and software. Notably, IDEXX benefits from a highly recurring revenue model, with 76% of its sales coming from consumables and services, ensuring stable and predictable cash flows. Software subscriptions, such as VetLab Station and practice management systems, further enhance retention and customer stickiness.
IDEXX’s profitability remains robust, with a 2023 gross margin of 59.5%, despite minor compression due to inflationary pressures. The company’s adjusted EBITDA margin stood at 31%, while its GAAP operating margin reached 25.6%, underscoring its strong pricing power and operational efficiency. The net profit margin was an impressive 21.8%, reflecting the company’s ability to convert revenue into sustainable earnings. IDEXX’s consistent reinvestment in innovation is a key driver of its competitive advantage, with $277 million allocated to R&D in 2023 (7.6% of revenue). This investment fuels advancements in diagnostic testing, cloud-based veterinary software, and automation tools that enhance clinic efficiency. Proprietary biomarker tests, such as the Catalyst SDMA for early kidney disease detection, further differentiate IDEXX from competitors and strengthen its pricing power.
The company’s growth is anchored in several mission-critical markets experiencing secular tailwinds as it is expected to grow at a 9.5% CAGR through 2030, fueled by rising pet ownership, humanization trends, and increased spending on advanced veterinary care. IDEXX is well-positioned to capitalize on this shift with its in-clinic diagnostic tools and expanding ecosystem of software solutions. Similarly, the livestock and poultry diagnostics market is projected to grow from $4.2 billion in 2023 to $6.8 billion by 2030, driven by increasing global protein demand, heightened regulatory scrutiny, and the need for disease surveillance. IDEXX’s livestock testing solutions play a crucial role in ensuring food safety and biosecurity, particularly in emerging markets like Asia-Pacific, where meat production is surging. Meanwhile, the global water quality testing market is expected to reach $6.3 billion by 2030, with IDEXX’s microbial testing solutions in high demand amid rising contamination risks and regulatory mandates.
Beyond its core verticals, IDEXX has significant opportunities for expansion. Geographic penetration remains a key growth lever, with North America currently driving 65% of revenue, while Europe and Asia-Pacific represent untapped potential. Adjacent markets, such as equine health, aquaculture diagnostics, and biopharma services, could unlock over $1 billion in additional revenue. AI and automation initiatives also present an avenue for margin expansion, as IDEXX develops high-throughput analyzers and AI-driven diagnostic tools to address labor shortages and enhance clinical decision-making.
IDEXX stands at the forefront of an expanding industry, benefiting from secular trends like pet humanization, rising protein demand, water safety concerns, and the digital transformation of veterinary care. Its cloud-based platforms and AI-driven diagnostics make it indispensable to modern veterinary practices, reinforcing its competitive moat against rivals like Zoetis. The company’s strong brand loyalty and high-margin, recurring revenue model ensure stability and growth. Trading at a forward P/E of ~40x, below its 5-year average of 55x, IDEXX offers a rare GARP opportunity. As sentiment shifts, a rerating could unlock significant upside, rewarding investors who recognize its long-term potential.
IDEXX Laboratories, Inc. (IDXX) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge fund portfolios held IDXX at the end of the fourth quarter which was 42 in the previous quarter. While we acknowledge the risk and potential of IDXX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than IDXX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.